Novo Nordisk A S (NONOF) SEC Filings — 2024

Filings

• Novo Nordisk's CagriSema Shows Superior Weight Loss in Obesity Trial — 6-K · Dec 20, 2024
• Novo Nordisk Completes Acquisition of 3 Manufacturing Sites — 6-K · Dec 18, 2024
• Novo Nordisk Catalent Acquisition Cleared to Close — 6-K · Dec 16, 2024
• EMA backs Ozempic label update for kidney risk reduction — 6-K · Dec 13, 2024
• Novo Nordisk Initiates Share Repurchase Program — 6-K · Dec 9, 2024
• EU Approves Novo Holdings' Catalent Acquisition — 6-K · Dec 6, 2024
• Novo Nordisk Initiates Share Repurchase Program — 6-K · Dec 2, 2024
• Novo Nordisk Launches Share Repurchase Program — 6-K · Nov 25, 2024
• Novo Nordisk Reports Insider Share Transactions — 6-K · Nov 19, 2024
• Novo Nordisk Initiates Share Repurchase Program — 6-K · Nov 18, 2024
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Nov 14, 2024
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Nov 13, 2024
• Novo Nordisk Discloses Insider Trading Activity — 6-K · Nov 8, 2024
• Novo Nordisk Discloses Insider Share Transactions — 6-K · Nov 7, 2024